• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四磷酸腺苷(Ap4),正常血压兔眼眼压的生理调节剂。

Adenosine tetraphosphate, Ap4, a physiological regulator of intraocular pressure in normotensive rabbit eyes.

作者信息

Pintor Jesús, Peláez Teresa, Peral Assumpta

机构信息

Departmentos de Bioquimica, Escuela Universitaria Optica, Universidad Complutense de Madrid, Spain.

出版信息

J Pharmacol Exp Ther. 2004 Feb;308(2):468-73. doi: 10.1124/jpet.103.058669. Epub 2003 Nov 4.

DOI:10.1124/jpet.103.058669
PMID:14600249
Abstract

Adenosine 5' tetraphosphate, Ap(4), is a natural nucleotide present in many biological systems. This nucleotide has been found as a constituent of the nucleotide pool present in the aqueous humor of New Zealand rabbits. HPLC analysis confirmed its identity and calculated its concentration levels to be 197 +/- 21 nM. When applied topically to the rabbit eyes, this mononucleotide produced a reduction in the intraocular pressure, which was dose-dependent. The pD(2) value calculated from the dose-response curve was 7.28 +/- 0.47, which is equivalent to 52.48 nM. The time course of such intraocular pressure reduction presented a maximal decrease of IOP to 75.1 +/- 2.3% compared with the vehicle control value (100%), and the effect lasted for more than 2 h. Cross-desensitization studies demonstrated that Ap(4) effect was mediated via a P2X receptor in this system. P2 receptor antagonists suramin, pyridoxal phosphate 6-azophenyl-2',4'-disulfonic acid (PPADS), and reactive blue 2 (RB-2) showed that only the latter was able to revert the effect of Ap(4). Antagonists of adrenoceptors and cholinoceptors were able to partially reverse the effect of this nucleotide; this might indicate a connection with the neural mechanisms that control the intraocular pressure.

摘要

5'-四磷酸腺苷(Ap(4))是一种存在于许多生物系统中的天然核苷酸。这种核苷酸已被发现是新西兰兔房水中核苷酸池的组成成分。高效液相色谱分析证实了其身份,并计算出其浓度水平为197±21 nM。当局部应用于兔眼时,这种单核苷酸可使眼压降低,且呈剂量依赖性。根据剂量-反应曲线计算出的pD(2)值为7.28±0.47,相当于52.48 nM。这种眼压降低的时间过程显示,与载体对照值(100%)相比,眼压最大降低至75.1±2.3%,且该效应持续超过2小时。交叉脱敏研究表明,在该系统中Ap(4)的作用是通过P2X受体介导的。P2受体拮抗剂苏拉明、6-重氮苯基-2',4'-二磺酸磷酸吡哆醛(PPADS)和活性蓝2(RB-2)表明,只有后者能够逆转Ap(4)的作用。肾上腺素能受体和胆碱能受体拮抗剂能够部分逆转这种核苷酸的作用;这可能表明其与控制眼压的神经机制有关。

相似文献

1
Adenosine tetraphosphate, Ap4, a physiological regulator of intraocular pressure in normotensive rabbit eyes.四磷酸腺苷(Ap4),正常血压兔眼眼压的生理调节剂。
J Pharmacol Exp Ther. 2004 Feb;308(2):468-73. doi: 10.1124/jpet.103.058669. Epub 2003 Nov 4.
2
Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure.房水中二腺苷多磷酸的存在:它们对眼压的影响。
J Pharmacol Exp Ther. 2003 Jan;304(1):342-8. doi: 10.1124/jpet.102.041368.
3
Adenine nucleotide effect on intraocular pressure: Involvement of the parasympathetic nervous system.腺嘌呤核苷酸对眼压的影响:副交感神经系统的参与。
Exp Eye Res. 2009 Jun 15;89(1):63-70. doi: 10.1016/j.exer.2009.02.010. Epub 2009 Feb 27.
4
Hypotensive effect of UDP on intraocular pressure in rabbits.尿苷二磷酸对兔眼压的降压作用。
Eur J Pharmacol. 2008 Jan 28;579(1-3):93-7. doi: 10.1016/j.ejphar.2007.10.040. Epub 2007 Oct 25.
5
The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.使用拮抗剂来鉴定介导α,β-亚甲基腺苷5'-三磷酸使大鼠离体迷走神经去极化的受体。
Br J Pharmacol. 1994 May;112(1):282-8. doi: 10.1111/j.1476-5381.1994.tb13065.x.
6
Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.新型 C 型利钠肽类似物 TAK-639 在兔、犬和猴体内的药代动力学和降眼压活性。
Exp Eye Res. 2019 Dec;189:107836. doi: 10.1016/j.exer.2019.107836. Epub 2019 Oct 15.
7
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.卡麦角林:药理学、多种物种的眼压降低研究以及食蟹猴眼中房水动力学调节
Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1.
8
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder.PPADS可选择性拮抗兔膀胱中P2X嘌呤受体介导的反应。
Br J Pharmacol. 1993 Dec;110(4):1491-5. doi: 10.1111/j.1476-5381.1993.tb13990.x.
9
Design and pharmacology of selective P2-purinoceptor antagonists.选择性P2嘌呤受体拮抗剂的设计与药理学
J Auton Pharmacol. 1996 Dec;16(6):341-4. doi: 10.1111/j.1474-8673.1996.tb00049.x.
10
Effect of diinosine polyphosphates on intraocular pressure in normotensive rabbits.二核苷酸多聚磷酸酯对正常眼压兔眼内压的影响。
Exp Eye Res. 2012 Aug;101:49-55. doi: 10.1016/j.exer.2012.05.011. Epub 2012 Jun 4.

引用本文的文献

1
The vasoconstrictor adenosine 5'-tetraphosphate is a danger signal that induces IL-1β.血管收缩剂5'-四磷酸腺苷是一种诱导白细胞介素-1β的危险信号。
Mol Med. 2025 Feb 21;31(1):72. doi: 10.1186/s10020-025-01116-6.
2
Beyond Triphosphates: Reagents and Methods for Chemical Oligophosphorylation.超越三磷酸酯:化学寡磷酰化的试剂和方法。
J Am Chem Soc. 2022 May 4;144(17):7517-7530. doi: 10.1021/jacs.1c07990. Epub 2022 Apr 26.
3
A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.一种基于 P2Y6 受体激动剂的治疗青光眼的有前途的候选药物。
Purinergic Signal. 2018 Sep;14(3):271-284. doi: 10.1007/s11302-018-9614-7. Epub 2018 Jul 17.
4
Purinergic dysregulation causes hypertensive glaucoma-like optic neuropathy.嘌呤能调节紊乱导致高血压性青光眼样视神经病变。
JCI Insight. 2017 Oct 5;2(19):93456. doi: 10.1172/jci.insight.93456.
5
Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits.P2Y(2) 受体沉默可降低新西兰兔眼内压。
Br J Pharmacol. 2012 Feb;165(4b):1163-72. doi: 10.1111/j.1476-5381.2011.01586.x.
6
2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.2-MeS-β,γ-CCl2-ATP 是一种降低眼内压的有效药物。
J Med Chem. 2010 Apr 22;53(8):3305-19. doi: 10.1021/jm100030u.
7
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.国际药理学联合会LVIII:P2Y G蛋白偶联核苷酸受体的最新进展:从分子机制、病理生理学到治疗
Pharmacol Rev. 2006 Sep;58(3):281-341. doi: 10.1124/pr.58.3.3.